Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
Express News | Spyre Therapeutics Shares up 6.1% After Evercore ISI Initiates Coverage With Outperform Rating
Express News | Spyre Therapeutics Inc : Evercore ISI Initiates Coverage With Outperform Rating
Evercore Initiates Spyre Therapeutics(SYRE.US) With Buy Rating
Express News | Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024
Express News | Spyre to Present Interim Spy001 Data by Year-End 2024
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics Down Nearly 20%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Updated Share Structure
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Express News | Spyre Therapeutics Appoints Accomplished Biopharma Leader DR. Sandra Milligan to Its Board of Directors
Positive Outlook on Spyre Therapeutics' IBD Pipeline and Financial Stability
Spyre Therapeutics Is Maintained at Overweight by Wells Fargo
Express News | Spyre Therapeutics, Inc. : Wells Fargo Raises Target Price to $40 From $35
Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook
Spyre Therapeutics Is Maintained at Buy by BTIG